{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:41:04Z","timestamp":1791405664750,"version":"4.3.3"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01519","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T05:41:11Z","timestamp":1579844471000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":72,"title":["Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future"],"prefix":"10.3389","volume":"9","author":[{"given":"Fabio","family":"Nicolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bocchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bronte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Delmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Guidoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Crin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA A Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/10937404.2016.1193361","article-title":"Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles","volume":"19","author":"Andujar","year":"2016","journal-title":"J Toxicol Environ Health B Crit Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008","volume":"19","author":"Henley","year":"2013","journal-title":"Int J Occup Environ Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nature Reviews Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms19040988","article-title":"NF2\/Merlin inactivation and potential therapeutic targets in mesothelioma","volume":"19","author":"Sato","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/JTO.0b013e31816fca1b","article-title":"Trimodality treatment of malignant pleural mesothelioma","volume":"3","author":"Batirel","year":"2008","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"E254","DOI":"10.3978\/j.issn.2072-1439.2013.11.28","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J Thorac Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/JTO.0b013e31824ab6c5","article-title":"Pleurectomy\/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma","volume":"7","author":"Lang-Lazdunski","year":"2012","journal-title":"J Thorac Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/SLA.0000000000000903","article-title":"Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients","volume":"260","author":"Sugarbaker","year":"2014","journal-title":"Ann Surg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.athoracsur.2016.08.071","article-title":"Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years","volume":"103","author":"Friedberg","year":"2017","journal-title":"Ann Thorac Surg."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.18632\/oncotarget.22062","article-title":"Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1097\/JTO.0b013e3182288af9","article-title":"Pleurectomy\/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma","volume":"6","author":"Lang-Lazdunski","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jtcvs.2019.07.073","article-title":"Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma - a phase I trial","volume":"159","author":"Opitz","year":"2019","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1067\/mtc.2001.116560","article-title":"A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"122","author":"Rusch","year":"2001","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","article-title":"A feasibility study evaluating surgery for mesothelioma after radiation therapy: the \u201cSMART\u201d approach for resectable malignant pleural mesothelioma","volume":"9","author":"Cho","year":"2014","journal-title":"J Thorac Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"151","author":"de Perrot","year":"2016","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jtcvs.2019.02.129","article-title":"Return to intended oncologic treatment after surgery for malignant pleural mesothelioma","volume":"158","author":"Nelson","year":"2019","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.18.01678","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial","volume":"37","author":"Bayman","year":"2019","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: ASCO clinical practice guidelines","volume":"36","author":"Kindler","year":"2018","journal-title":"JCO."},{"key":"B26","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ijrobp.2015.06.029","article-title":"Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors","volume":"93","author":"Minatel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.ijrobp.2011.09.027","article-title":"Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"83","author":"Rosenzweig","year":"2012","journal-title":"Int J Radiat Oncol Biol. Phys."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1016\/j.prro.2014.11.005","article-title":"Early experience with intensity modulated proton therapy for lung-intact mesothelioma: a case series","volume":"5","author":"Pan","year":"2015","journal-title":"Pract Radiat Oncol."},{"key":"B30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.37549\/ARO1107","article-title":"Volumetric-modulated arc therapy for malignant pleural meso- thelioma after pleurectomy\/decortication","volume":"5","author":"Dumane","year":"2016","journal-title":"Appl Rad Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2016.12.004","article-title":"A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: the Ontario Clinical Oncology Group","volume":"104","author":"Laurie","year":"2017","journal-title":"Lung Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J Natl Compr Canc Netw."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","article-title":"Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"12","author":"Tsao","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"JCO1900269","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-na\u00efve patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J Clin Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jtho.2016.01.014","article-title":"A randomized phase 2 study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes","volume":"11","author":"Buikhuisen","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10637-019-00783-7","article-title":"A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma","volume":"17","author":"van Brummelen","year":"2019","journal-title":"Invest New Drugs"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.celrep.2016.06.097","article-title":"Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1","volume":"16","author":"Locke","year":"2016","journal-title":"Cell Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with arginino-succinate synthetase 1-deficient thoracic cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J Clin Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumour suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B51","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca(2+) flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature."},{"key":"B52","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/ijms20020429","article-title":"BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment","volume":"20","author":"Guazzelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.lungcan.2018.12.004","article-title":"Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma","volume":"127","author":"Kumar","year":"2019","journal-title":"Lung Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.canlet.2016.05.011","article-title":"CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma","volume":"378","author":"Betti","year":"2016","journal-title":"Cancer Lett."},{"key":"B56","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J Med Genet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B58","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5306\/wjco.v7.i2.135","article-title":"Targeting enhancer of zeste homolog 2 as a promising strategy for cancer treatment","volume":"7","author":"Marchesi","year":"2016","journal-title":"World J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"8515","DOI":"10.1200\/JCO.2018.36.15_suppl.8515","article-title":"Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R\/R) malignant mesothelioma (MM) with BAP1 inactivation","volume":"36","author":"Zauderer","year":"2018","journal-title":"JCO."},{"key":"B62","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","article-title":"FAK signaling in human cancer as a target for therapeutics","volume":"146","author":"Lee","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumours","volume":"27","author":"Soria","year":"2016","journal-title":"Ann Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND\u2014a double-blind, randomized, phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"JCO"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br J Cancer."},{"key":"B66","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/17476348.2019.1563488","article-title":"Immunotherapy strategies for mesothelioma \u2013 the role of tumor specific neoantigens in a new era of precision medicine","volume":"13","author":"Ye","year":"2019","journal-title":"Expert Rev Respir Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1513\/AnnalsATS.201506-315LE","article-title":"Spontaneous regression of malignant pleural mesothelioma in a patient with new-onset inflammatory arthropathy","volume":"12","author":"Moser","year":"2015","journal-title":"Ann Am Thorac Soc."},{"key":"B68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0169-5002(00)00217-8","article-title":"Localised spontaneous regression in mesothelioma\u2013possible immunological mechanism","volume":"32","author":"Robinson","year":"2001","journal-title":"Lung Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1089\/jir.2014.0054","article-title":"Successful combined intratumoural immunotherapy of established murine mesotheliomas requires B-cell involvement","volume":"35","author":"Krishnan","year":"2015","journal-title":"J Interferon Cytokine Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumour-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumour- infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother."},{"key":"B72","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3389\/fimmu.2017.00961","article-title":"Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumour cells","volume":"8","author":"Gibbons Johnson","year":"2017","journal-title":"Front Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e1356146","DOI":"10.1080\/2162402X.2017.1356146","article-title":"Temporal and spatial heterogeneity of programmed cell death 1-ligand 1 expression in malignant mesothelioma","volume":"6","author":"Terra","year":"2017","journal-title":"Oncoimmunology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"S324","DOI":"10.1016\/j.jtho.2016.11.347","article-title":"OA20.06 prospective immunogenomic profiling of non-small cell lung cancer - The ICON Project","volume":"12","author":"Sepesi","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1 and PD-L1 antibodies in cancer: current status and future directions","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol Immunother."},{"key":"B77","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1164\/rccm.201608-1755CI","article-title":"Checkpoint blockade in lung cancer and mesothelioma","volume":"196","author":"Lievense","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2217\/imt-2016-0002","article-title":"Immune checkpoint inhibitor combinations in solid tumours: opportunities and challenges","volume":"8","author":"Kyi","year":"2016","journal-title":"Immunotherapy"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"OA13.01 a phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopies","volume":"12","author":"Quispel-Janssen","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","article-title":"CONFIRM: a double-blind, placebo- controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial","volume":"19","author":"Fennell","year":"2018","journal-title":"Trials."},{"key":"B84","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"OA08.03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"v931","DOI":"10.1093\/annonc\/mdz394.091","article-title":"LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the european thoracic oncology platform (ETOP 9\u201315) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Annonc."},{"key":"B88","doi-asserted-by":"publisher","first-page":"CT039","DOI":"10.1158\/1538-7445.AM2017-CT039","article-title":"Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors","volume":"77","author":"Angevin","year":"2017","journal-title":"Cancer Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"LBA8507","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA8507","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial","volume":"35","author":"Scherpereel","year":"2017","journal-title":"JCO."},{"key":"B90","doi-asserted-by":"publisher","first-page":"TPS8581","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8581","article-title":"Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma","volume":"35","author":"Zalcman","year":"2017","journal-title":"JCO"},{"key":"B91","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"18429","DOI":"10.18632\/oncotarget.4384","article-title":"miR-29b attenuates tumourigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2","volume":"6","author":"Chung","year":"2015","journal-title":"Oncotarget"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.biopha.2017.08.088","article-title":"MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 (CDX1) in glioma cells","volume":"95","author":"Yang","year":"2017","journal-title":"Biomed Pharmacother."},{"key":"B94","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2008.04.001","article-title":"miRiad roles for the miR-17-92 cluster in development and disease","volume":"133","author":"Mendell","year":"2008","journal-title":"Cell."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccr.2007.03.012","article-title":"Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics","volume":"11","author":"MacDiarmid","year":"2007","journal-title":"Cancer Cell."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e20069","DOI":"10.1200\/JCO.2019.37.15_suppl.e15653","article-title":"The combined treatment of 150 kHz tumor treating fields (TTFields) and cisplatin or pemetrexed inhibits mesothelioma cells in vitro and in vivo","volume":"37","author":"Weinberg","year":"2019","journal-title":"JCO"},{"key":"B99","doi-asserted-by":"publisher","first-page":"S397","DOI":"10.1016\/j.jtho.2018.08.416","article-title":"MA12.06 STELLAR - final results of a phase 2 trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma","volume":"13","author":"Ceresoli","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A trial of intrapleural adenoviral-mediated Interferon-\u03b12b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"S746","DOI":"10.1016\/j.jtho.2018.08.1266","article-title":"P2.06\u201311 a phase I\/II study of intrapleural Ad-SGE-REIC administration in patients with refractory malignant pleural mesothelioma","volume":"13","author":"Goto","year":"","journal-title":"J Thorac Oncol."},{"key":"B103","first-page":"466","article-title":"Use of a \u201creplication-restricted\u201d herpes virus to treat experimental human malignant mesothelioma","volume":"57","author":"Kucharczuk","year":"1997","journal-title":"Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"v122","DOI":"10.1093\/annonc\/mdx367.001","article-title":"366PDOncolytic herpesvirus therapy for mesothelioma: a phase I\/IIa trial of intrapleural administration of HSV1716 (NCT01721018)","volume":"28","author":"Danson","year":"2017","journal-title":"Annonc"},{"key":"B105","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3389\/fonc.2017.00179","article-title":"Oncolytic viral therapy for mesothelioma","volume":"7","author":"Pease","year":"2017","journal-title":"Front Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumour control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood.V124.21.310.310","article-title":"Vaccination with WT1 mRNA-electroporated dendritic cells: report of clinical outcome in 66 cancer patients","volume":"124","author":"Berneman","year":"2014","journal-title":"Blood."},{"key":"B110","doi-asserted-by":"publisher","first-page":"TPS7586","DOI":"10.1200\/jco.2015.33.15_suppl.tps7586","article-title":"Phase I\/II study of tumour-infiltrating lymphocyte (TIL) infusion and low-dose interleukin-2 (IL-2) in patients with advanced malignant pleural mesothelioma (MPM)","volume":"33","author":"Doherty","year":"2015","journal-title":"JCO"},{"key":"B111","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"abstr 2509","DOI":"10.1200\/JCO.2016.34.15_suppl.2509","article-title":"Phase I study of anti-mesothelin antibody-drug conjugate anetumab ravtansine (AR)","volume":"34","author":"Blumenschein","year":"2016","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.328","article-title":"OA 02.01 randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma","volume":"12","author":"Kindler","year":"","journal-title":"J Thorac Oncol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-16-1667","article-title":"Efficacy of anti-mesothelin immunotoxin RG7787 plus Nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor response","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Live-attenuated, Listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy for treatment of malignant pleural mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","article-title":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","volume":"187","author":"Zeltsman","year":"2017","journal-title":"Transl Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumour","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumour activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumour immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e26722","DOI":"10.1371\/journal.pone.0026722","article-title":"An in vivo platform for tumor biomarker assessment","volume":"6","author":"Servais","year":"2011","journal-title":"PLoS ONE."},{"key":"B122","doi-asserted-by":"publisher","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2019-CT036","article-title":"Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy","volume":"79","author":"Adusumilli","year":"2019","journal-title":"Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"JCO"},{"key":"B124","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein- specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J Transl Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"v501","DOI":"10.1093\/annonc\/mdz253.052","article-title":"1226PA phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells","volume":"30","author":"Curioni","year":"2019","journal-title":"Annonc."},{"key":"B126","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-07-0110","article-title":"Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors","volume":"13","author":"Inamoto","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1084\/jem.172.2.649","article-title":"Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family","volume":"172","author":"Dang","year":"1990","journal-title":"J Exp Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/bjc.2017.62","article-title":"First-in- human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers","volume":"116","author":"Angevin","year":"2017","journal-title":"Br J Cancer."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/14737140.2016.1241150","article-title":"Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil","volume":"16","author":"Nakano","year":"2016","journal-title":"Expert Rev Anticancer Ther."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01519\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T16:03:41Z","timestamp":1695657821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01519\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":129,"alternative-id":["10.3389\/fonc.2019.01519"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01519","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"article-number":"1519"}}